European parliamentarians today call for a
moratorium on xenotransplantation
STRASBOURG, 29.01.99 - European parliamentarians today called for a
moratorium on xenotransplantation until this new technology - which uses animal parts for
human transplants - is evaluated and guidelines established and agreed.
Fears of a threat to public health promoted the COUNCIL OF EUROPE's Parliamentary
Assembly to call for the world-wide ban. " The risks involved in allowing
xenotransplantation in clinics is currently too high to be acceptable. Much more research
is needed before we will have satisfactorily answered all the unanswered questions,"
said Jean-Francois MATTEI (France, LDR), who presented the report in the absence of its
author Gian Reto PLATTNER (Switzerland, Soc).
Mr Mattei said that although transplant technology could be of benefit, and tissue from
pigs was already used in heart valve operations, careful study was necessary.
A major obstacle to the current use of human tissues for transplants was the lack of
donors, he said. In the USA alone some 50,000 patients were awaiting transplants from the
less than 5000 annual donors and around 3000 people die a year because no donor is
available. Using animal tissue would up the availability of organs, and gene therapy could
also help circumvent the problems of donor rejection.
But the serious risk of disease transfer had to be weighed against the potential
benefits said Mr Mattei. Virulent viral diseases such as Ebola and Marburg were known to
transmit from monkeys to humans and recent evidence has suggested that diseases such as
Creuzfeldt Jakob originated in animal spongiform encephalopathies such as mad cow disease.
The Assembly also asked the Council of Europe Public Health and Bioethics Committees to
work hand in hand with the World Health Organisation on a strategy which balances ethical,
medical, scientific, legal, social and public health issues before human clinical trials
continue.
Press Contact
Cathie Burton or Christiane Dennemeyer, Council of Europe Press Service
Tel. +33 3 88 41 28 93 ou +33 3 88 41 25 63 - Fax. +33 3 88 41 27 89
E-mail: PressUnit@coe.fr
| 
